Report Archive
All Research
Page 17 of 52 · 1238 reports
41/100
THK: A Category-Defining Linear-Motion Franchise Re-Rated on Restructuring and a Still-Unbooked Robotics Option
THK is the Japanese precision-component maker that commercialized the world's first LM Guide and still leads in linear-motion hardware (LM guides, ball screws, actuators) sold into machine tools, electronics, and factory automation. After exiting a low-return automotive business and adopting an ROE-above-10% policy, continuing-operations earnings are recovering toward 2026 guidance of revenue around 276 billion yen and operating income around 31 billion yen, yet at 7,802 yen the stock trades near 38.5x forward EPS and 3.3x book, pricing in both the restructuring and a robotics optionality the filings do not yet quantify. Rating Hold: a real industrial franchise whose stock has run ahead of delivered execution, with an ideal buy zone of 3,900 to 4,100 yen.
43/100
Nabtesco: A Scarce Robot-Reducer Franchise Carrying a Growth Premium on a Still-Cyclical Base
Nabtesco is a diversified Japanese precision-machinery group whose profit engine is industrial-robot RV reducers, where it holds about 60% of the global market for medium- to large-joint reducers, backed by transport, aircraft, marine, and door-system businesses. FY2025 continuing-operations sales rose 9.8% and operating income 60.3%, yet at JPY 5,707 the stock trades near record highs at roughly 36x FY2026 EPS and 43x FY2025 EPS, pricing in both the cyclical recovery and a large slice of still-unproven humanoid optionality. Rating Watch: a genuine franchise on a capital-heavy cyclical base, with no margin of safety until the mid-3,000s.
44/100
Shenzhen Zhaowei: A Real Precision Micro-Drive Business Undergoing a Thematic Robot Re-Rating
Zhaowei is a 25-year-old precision micro-drive systems supplier whose 2025 revenue was RMB1.72 billion, with automotive the real engine at 64.5% of sales while the headline-grabbing embodied-robotics line was just 1.39%. The A-share trades at about 91.5x trailing earnings and the H-share implies a roughly 46.6% discount, so the market is pre-paying for a humanoid-supply-chain future that the filings have not yet delivered. Rating Hold: a credible micro-drive platform with real robot optionality, but the A-share still prices too much of that optionality in advance; the ideal buy zone is CN¥44-61.
50/100
Akeso, Inc.: A Commercial-Stage Antibody Innovator Still Priced on Ivonescimab's Global Option Value
Akeso is a commercial-stage Chinese antibody innovator with seven marketed products and record 2025 commercial sales of RMB3.03 billion, anchored by cadonilimab and ivonescimab. Yet the stock trades as a referendum on one molecule: whether ivonescimab's strong China data (a HARMONi-6 overall-survival win, HR 0.66) can survive global regulators, while 2025 operating cash flow stayed negative at RMB947.6 million and the shares fetch about 22x trailing sales. Rating Hold: rare science and a real China franchise, but the price still pre-pays too much of ivonescimab's ex-China upside; the ideal buy zone is HK$58-64.
49/100
XtalPi Holdings: An AI-for-Science Platform Climbing from Fee-for-Service Work to Milestone Economics, Still Priced Ahead of Proof
XtalPi is a founder-led AI-for-science platform built by MIT-trained physicists, selling drug-discovery and R&D-automation solutions as it tries to climb from fee-for-service work toward milestone-and-royalty economics. 2025 revenue jumped 201.2% to RMB802.6 million as drug-discovery solutions rose to RMB537.9 million from RMB103.7 million, but one customer was over 45% of sales, reported profit leaned on RMB514.0 million of fair-value gains, and operating cash flow stayed negative at RMB-165.4 million. Rating Hold: serious science with blue-chip partners (DoveTree, Lilly, Pfizer) and a large cash cushion, yet the price still pays for cleaner, broader earnings than the platform has delivered; the ideal buy zone is HK$3.8-4.1.
51/100
Asymchem Laboratories: A Proven Small-Molecule CDMO in Transition to New Modalities, Already Priced for Success
Asymchem is a founder-led Chinese CDMO anchored in commercial small-molecule process chemistry, with emerging peptide, oligonucleotide and biologics work now about 30% of revenue. 2025 revenue rose 14.9% to RMB 6.67bn with adjusted net profit of RMB 1.25bn, order backlog reached US$1.385bn (+31.65%), and Q1 2026 emerging-business revenue jumped 74.1% — yet the A-share trades near 40x trailing earnings (about a 2.4% owner-earnings yield), while founder-concentrated governance and the BIOSECURE policy overhang cap the multiple. Rating Hold: a high-quality chemistry franchise whose new-modality transition is real, but the current price already pays for most of the 2026 recovery; the ideal buy zone is CNY 68-70.
U.S. Market Close Daily | 2026-06-23
U.S. equities logged a rotation-led pullback as AI and semiconductor selling hit the Nasdaq while defensives and lower Treasury yields cushioned broader stress.
43/100
24Buffett
Energy Transfer LP: A Discounted Midstream Cash Cow Turning Its Asset Empire Into Disciplined Gas-Led Growth
Energy Transfer is a roughly $66bn K-1 master limited partnership that owns about 140,000 miles of integrated U.S. gas, NGL, crude and export infrastructure across 44 states, throwing off $8.20bn of distributable cash flow to partners against a $4.56bn payout, or about 1.8x coverage. Its 2026 EBITDA guidance has been raised twice to $18.2bn-$18.6bn as a gas-and-NGL project backlog converts to cash, yet a 2020 distribution cut, MLP governance frictions and heavy reinvestment keep the units on a roughly 7.1% yield and a persistent structure discount. Rating Hold: integrated bottlenecks support a safe payout and organic reacceleration, but the discount closes only partly until disciplined execution is proven through repetition rather than another deal.
42/100
89Buffett
Graco Inc.: A Premium Fluid-Handling Compounder Priced for a Recovery Not Yet Visible
Graco is a century-old, distributor-led fluid-handling equipment maker with premium-industrial economics — high-20s operating margins, ~23% ROIC, and ~40% of revenue from parts and accessories. But organic sales fell 6% in Q1 2026 and reported growth now leans on bolt-on M&A (Valco Melton at ~14x EBITDA), while the stock trades near 24.8x earnings with no margin of safety. Rating Hold: a good company at an ordinary price, already priced for a cleaner recovery than the evidence yet shows.
42/100
MKS Inc.: A Hybrid Process-Control Platform Priced for a Near-Best-Case AI Cycle
MKS is a picks-and-shovels supplier of vacuum, photonics, and materials and chemistry technologies to semiconductor and advanced-packaging manufacturing, reshaped by the 2022 Atotech deal into a hybrid that is part cyclical subsystem vendor and part recurring-chemistry platform. Full-year 2025 revenue reached US$3.93 billion with semiconductor and electronics-and-packaging both growing double digits, and the February 2026 refinancing eased the post-Atotech debt strain, yet at about US$406 the stock trades near 34x trailing EBITDA and 52x non-GAAP earnings. Rating Avoid: a genuinely better business than two years ago, but the price already discounts a near-best-case AI and packaging cycle, with a margin of safety only opening below roughly US$180.
44/100
Renesas: A Cyclical Embedded Compounder Priced for a Transition Still Unproven
Renesas is a cyclical embedded-semiconductor compounder centered on automotive MCUs, with analog, power, and connectivity layers and a new system-design software push after Altium. Q1 2026 non-GAAP revenue rose 20.6% to JPY 372.3 billion at a 59.2% gross margin, and 2025 free cash flow reached JPY 328.2 billion, yet IFRS profit swung to a loss on Wolfspeed-related impairments. Rating Hold: a real franchise with better cash than the headlines, but at JPY 4,734 the price already discounts much of the recovery, with a wider margin of safety only opening in the JPY 3,500-3,800 range.
40/100
59Buffett
Inventec: An AI-Server Manufacturer Still Earning Assembly Margins
Inventec is a Taiwan ODM/EMS maker that has shifted from a notebook-led business to a server-led one, with servers above half of sales on the AI build-out. Q1 2026 revenue rose 28% to NT$200.3 billion, yet gross margin slipped to 5.1% and operating cash flow has converted only about 0.8x of net income over 2021-2025, so AI growth is still monetized through thin, working-capital-heavy assembly economics. Rating Hold: a better business than its old notebook-ODM image, but at NT$67.7 the stock already prices in much of the transition, with a wide margin of safety only opening in the low-to-mid NT$40s.
48/100
Leaderdrive: China's Harmonic-Reducer Leader Priced for a Humanoid Future
Leaderdrive is China's domestic leader in harmonic-drive (strain-wave) reducers, the precision part inside robot joints, now extending from stand-alone components into mechatronic actuators. 2025 revenue jumped 47.3% to RMB 570.7 million with harmonic-reducer unit sales up 72.5%, yet at RMB 381.60 the stock trades near 123x sales and roughly 562x trailing earnings, pre-spending a humanoid-scale future that filings have not yet disclosed. Rating Avoid: a genuinely improving component leader at a speculative price, with every valuation scenario implying a loss from today's level until the humanoid ramp is proven or the price resets.
50/100
70Buffett
Auras Technology: A Thermal Vendor Climbing the AI Liquid-Cooling Stack
Auras is a Taiwanese thermal-management vendor shifting from legacy air cooling to higher-value AI-server liquid cooling, with 2025 revenue up 47.6% to TWD 23.28 billion. The mix shift is real (2026 Q1 liquid-cooling revenue passed 55% and gross margin reached 29.7%), but 2025 operating cash flow turned negative and the stock near 30.6x trailing earnings already discounts much of the 2026-2027 ramp. Rating Hold: genuine liquid-cooling share gains are visible, yet a wide margin of safety only opens below roughly TWD 690.
42/100
LG Energy Solution: Strategic Assets, Unproven Returns
LG Energy Solution is the largest Korean large-format battery maker, running a three-part machine of automotive cells for global OEMs, IRA-localized North American capacity, and a fast-growing energy-storage pivot, with 2025 revenue of ₩23.7tn. The 2026 question is whether it can earn real returns on a ₩42.6tn asset base: Q1 2026 still posted a ₩207.8bn operating loss even after ₩189.8bn of AMPC credits, though 46-series backlog has topped 440 GWh and ESS is becoming a credible second leg. Rating Hold: at ₩404,500 the stock trades near 4.0x sales and already prices a recovery, leaving no clear margin of safety until ex-credit profitability inflects.
48/100
24Buffett
Triple Flag Precious Metals: Quality Compounder, Fully Priced
Triple Flag is a gold-focused streaming and royalty financier that funds miners and collects metal for years at fixed terms, running a 242-asset book at a 93% asset margin with little operating drag. FY2025 revenue reached US$388.7 million with US$312.8 million operating cash flow, yet at US$30.05 the stock trades above its ideal-buy zone, with Northparkes alone at 26% of consensus NAV. Rating Watch: a high-quality compounder still in transition to senior scale, attractive on quality but not yet on price.
48/100
Asana: Optically Cheap, Strategically Unproven
Asana is a mid-cap, seat-based work-management SaaS now layering consumption-based AI onto a maturing land-and-expand model, with almost all of its $790.8 million FY2026 revenue still tied to the flagship platform. The 2026 story is a clean bull-bear standoff: margins inflected to a $56.7 million FY2026 non-GAAP operating profit and AI products already reached 17% of net-new ARR in Q1 FY2027, yet revenue growth has slowed to high single digits and management still flags PLG as a roughly two-point drag. Rating Watch: the stock is optically cheap at about 1.5x forward EV/revenue, but it needs firmer proof that AI can offset seat-growth maturity before the discount closes.
49/100
Merck KGaA: A Diversified Science Platform in Transition
Merck KGaA, Darmstadt is a family-controlled German science-and-technology group whose €21.1 billion of 2025 sales come from three very different engines: a patent-exposed Healthcare arm, a high-quality Life Science tools franchise and a semiconductor-materials Electronics business. The 2026 stock is a tug of war, because a known Mavenclad U.S. patent cliff drags Healthcare while Process Solutions compounds near 10% organically and Electronics rides advanced-node AI demand, leaving the shares near 15.9 times 2025 EPS pre and a 3.5% free-cash-flow yield after a May rebound to €133.05. Rating Hold: genuinely strong Life Science and semiconductor-materials engines offset a credibility-damaged Healthcare arm, but a permanent KGaA governance discount and only-fair valuation keep upside limited.
51/100
Sartorius AG: A Quality Bioprocess Recovery Already in the Price
Sartorius AG is a German life-science tools group whose value is dominated by its majority-owned bioprocess franchise, Sartorius Stedim Biotech, with the liquid quotation being the non-voting preference share SRT3. After a pandemic boom and a destocking bust, 2025 sales recovered 7.6% to about EUR 3.54 billion, underlying EBITDA margin returned to 29.7%, and leverage fell from 3.96x to 3.55x, yet roughly EUR 3.74 billion of net debt and a still-premium 18x trailing EBITDA leave little cushion. Rating Hold: the franchise and the recovery are both real, but the market already sees the normalization and the current EUR 217.10 price sits above the report's ideal buy zone.
45/100
40Buffett
TAL Education Group: A Cash-Rich Rebuild with a Hardware Question
TAL is a cash-rich China education company rebuilt around legal enrichment classes, learning devices, and content after the 2021 tutoring crackdown. FY2026 revenue reached about US$3.01 billion (up 33.7%) and net cash is roughly US$3.24 billion, but reported earnings are flattered by about US$347 million of non-operating gains and VIEs supplied 78.6% of revenue. Rating Hold: the rebuild is real, yet normalized earnings, device durability, and China-structure risk leave the stock fairly priced rather than compelling.
46/100
ALS Limited: A High-Quality Compounder with a Cyclical Sidecar
ALS Limited is a global laboratory-testing group that earns most of its revenue from Life Sciences yet a disproportionate share of margin from minerals-related Commodities testing, so a diversified TIC provider still trades, at key moments, like a high-quality miner's service proxy. FY26 delivered record revenue of A$3.32 billion and an 18.0% underlying EBIT margin, hitting the FY27 strategic targets a year early, but at A$23.36 the stock trades near 37 times trailing EPS with the margin of safety put at zero. Rating Hold: a strong dual-engine testing franchise whose price already discounts commodities strength, acquisition repair and future hub productivity, leaving little room for disappointment.
44/100
Omron Corporation: A Company in Transition, Fairly Priced
Omron is a Japanese automation group whose profit engine is Industrial Automation (sensors, controllers, motion, safety, and vision), cushioned by a steadier healthcare leg built on a global lead in home blood-pressure monitors. FY2026 continuing-operations sales reached ¥767.4 billion at an operating margin under 8%, far below Keyence and Fanuc, while the planned sale of Device & Module Solutions concentrates the portfolio on automation and healthcare. Rating Hold: a genuine but cyclical franchise improving into a cleaner shape, yet at ¥5,830 it already prices in a recovery that has not broadened beyond AI-linked demand, leaving no margin of safety.
52/100
48Buffett
On Holding: Premium Growth, Priced for Perfection
On Holding is a Swiss premium performance-sportswear brand built on running footwear, monetizing a proprietary-technology product system through a fast-rising direct-to-consumer channel alongside selective wholesale. The bull-bear core is a rare combination of scale growth and margin expansion: fiscal 2025 net sales of CHF 3.014 billion, up 30.0% reported and 35.6% constant-currency, with gross margin climbing to 62.8% and DTC mix at 41.8%, set against a stock that at roughly 3.1x trailing sales and a trailing P/E near the high-40s already prices in continued near-flawless execution amid Vietnam-tariff and footwear-concentration risk. Rating Hold: premium growth and margin expansion are real, but today's price already demands sustained near-perfect execution, leaving no conservative-entry margin of safety.
48/100
24Buffett
Iridium: A Global Cash Machine With Option Premium
Iridium Communications operates the only truly global commercial L-band cross-linked LEO satellite network, selling mostly recurring service revenue for critical voice, IoT, and now timing connectivity where terrestrial networks fail. In 2025 it produced $871.7 million total revenue, $634.0 million service revenue, and $495.3 million OEBITDA, yet at roughly $6.25 billion enterprise value, about 12.6x 2025 OEBITDA, the stock already prices a strategic second curve in NTN Direct, PNT, and the planned Aireon deal against guidance of only flat-to-2% service growth in 2026. Rating Hold: a proven cash-generating global satellite asset whose current price already assumes meaningful success from NTN Direct, PNT, and aviation expansion.